[go: up one dir, main page]

GB201011819D0 - Neurodegenerative disorders - Google Patents

Neurodegenerative disorders

Info

Publication number
GB201011819D0
GB201011819D0 GBGB1011819.8A GB201011819A GB201011819D0 GB 201011819 D0 GB201011819 D0 GB 201011819D0 GB 201011819 A GB201011819 A GB 201011819A GB 201011819 D0 GB201011819 D0 GB 201011819D0
Authority
GB
United Kingdom
Prior art keywords
neurodegenerative disorders
neurodegenerative
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1011819.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB1011819.8A priority Critical patent/GB201011819D0/en
Publication of GB201011819D0 publication Critical patent/GB201011819D0/en
Priority to GB1306866.3A priority patent/GB2497502A/en
Priority to PCT/GB2011/051291 priority patent/WO2012007740A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB1011819.8A 2010-07-14 2010-07-14 Neurodegenerative disorders Ceased GB201011819D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB1011819.8A GB201011819D0 (en) 2010-07-14 2010-07-14 Neurodegenerative disorders
GB1306866.3A GB2497502A (en) 2010-07-14 2011-07-11 Neurodegenerative Disorders
PCT/GB2011/051291 WO2012007740A1 (en) 2010-07-14 2011-07-11 Neurodegenerative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1011819.8A GB201011819D0 (en) 2010-07-14 2010-07-14 Neurodegenerative disorders

Publications (1)

Publication Number Publication Date
GB201011819D0 true GB201011819D0 (en) 2010-09-01

Family

ID=42734915

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1011819.8A Ceased GB201011819D0 (en) 2010-07-14 2010-07-14 Neurodegenerative disorders
GB1306866.3A Withdrawn GB2497502A (en) 2010-07-14 2011-07-11 Neurodegenerative Disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1306866.3A Withdrawn GB2497502A (en) 2010-07-14 2011-07-11 Neurodegenerative Disorders

Country Status (2)

Country Link
GB (2) GB201011819D0 (en)
WO (1) WO2012007740A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632664B (en) * 2017-01-12 2020-07-10 沈阳药科大学 Apolipoprotein II/I and preparation method, biological function and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964598B2 (en) 1995-10-17 2011-06-21 The J. David Gladstone Institutes ApoE4 domain interaction inhibitors and methods of use thereof
WO2003045321A2 (en) * 2001-11-26 2003-06-05 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
WO2004038003A2 (en) * 2002-10-25 2004-05-06 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
WO2008024114A1 (en) * 2006-08-24 2008-02-28 Genizon Biosciences Inc. Genemap of the human genes associated with schizophrenia

Also Published As

Publication number Publication date
GB2497502A (en) 2013-06-12
GB201306866D0 (en) 2013-05-29
WO2012007740A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
AP3607A (en) Substituted imidazopyridazines
TWI560388B (en) Dampferzeugerheizrohrreparaturmittel und reparaturverfahren
GB201206982D0 (en) X-system
PL2534132T3 (en) Substituted pyrrolidine-2-carboxamides
ZA201304139B (en) Combination
ZA201304430B (en) Substituted sodium-1h-pyrazole-5-olate
PL2606715T3 (en) Baler-wrapper combination
PL3901164T3 (en) Gluten-related disorders
EP2572199A4 (en) Combination
EP2571358A4 (en) Combination
GB2512771B (en) Ablutionary fitting
EP2588088A4 (en) Solid forms
GB201306866D0 (en) Neurodegenerative Disorders
SI2607602T1 (en) Sunscreen
EP2603078A4 (en) Combination
GB201113102D0 (en) Zap it
GB201117693D0 (en) Combination
GB201116007D0 (en) Combination
GB201106339D0 (en) Combination
GB201121105D0 (en) Combination
GB201101836D0 (en) C It Now
GB201020548D0 (en) My clear step-plan
GB201120794D0 (en) Duo drinkster
GB201000737D0 (en) Dendrimers
EP2654755A4 (en) Combination

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)